Pub Date : 2019-01-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2019.01.011
Pengfei Liu, X. Duan
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been widely used in the treatment of hematologic diseases and other malignant solid tumors. However, there are also a series of problems after allo-HSCT, such as the recurrence of the primary disease, graft rejection (GR), graft versus host disease(GVHD) and so on, which may lead to the failure of transplantation, and are currently important problems affecting the efficacy of allo-HSCT. Dynamic monitoring of chimeric state of donor and recipient cells and timely corresponding clinical treatment have great significance to reduce the recurrence of disease, GR and GVHD. The chimeric state of T cells is related to the occurrence of GVHD after transplantation, and the higher the chimeric rate of T cells in the early stage, the more likely GVHD will occur. The chimeric state of B cells is often correlated with the recurrence after transplantation. In this paper, the clinical significance of dynamic monitoring of chimeric rate of patients after allo-HSCT was elaborated from the monitoring of chimeric rate of different immune cell subgroups and the factors influencing chimeric state, so as to further guide clinical treatment and intervention. Key words: Hematopoietic stem cell transplantation; Transplantation, homologous; Chimerism; Immunity, cellular; Graft vs host disease; Graft rejection
{"title":"Clinical significance on monitoring different immune cell chimerism of patients after allogeneic hematopoietic stem cell transplantation","authors":"Pengfei Liu, X. Duan","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.01.011","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.01.011","url":null,"abstract":"Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been widely used in the treatment of hematologic diseases and other malignant solid tumors. However, there are also a series of problems after allo-HSCT, such as the recurrence of the primary disease, graft rejection (GR), graft versus host disease(GVHD) and so on, which may lead to the failure of transplantation, and are currently important problems affecting the efficacy of allo-HSCT. Dynamic monitoring of chimeric state of donor and recipient cells and timely corresponding clinical treatment have great significance to reduce the recurrence of disease, GR and GVHD. The chimeric state of T cells is related to the occurrence of GVHD after transplantation, and the higher the chimeric rate of T cells in the early stage, the more likely GVHD will occur. The chimeric state of B cells is often correlated with the recurrence after transplantation. In this paper, the clinical significance of dynamic monitoring of chimeric rate of patients after allo-HSCT was elaborated from the monitoring of chimeric rate of different immune cell subgroups and the factors influencing chimeric state, so as to further guide clinical treatment and intervention. \u0000 \u0000 \u0000Key words: \u0000Hematopoietic stem cell transplantation; Transplantation, homologous; Chimerism; Immunity, cellular; Graft vs host disease; Graft rejection","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"42 1","pages":"65-71"},"PeriodicalIF":0.0,"publicationDate":"2019-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42442587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2019.01.005
Rong Li
Platelets are specialized cells, which are functioned to prevent bleeding and minimize blood vessel injury, and are also the predominating factor in the processes of hemostasis and thrombosis, while implicate in other processes including inflammation, innate immunity, angiogenesis and tumor metastasis. Among current mechanisms of platelet formation, platelets are produced by megakaryocytes, which are themselves generated by a process of controlled differentiation and maturation of bone marrow hematopoietic stem cells (HSC) and progenitor cells. Megakaryocytes release platelets by extending long, branching proplatelets, into sinusoidal blood vessels. Bone marrow cavity and extracellular matrix composition together with cytokines as thrombopoietin (TPO) are key regulators of megakaryopoiesis by supporting cell differentiation and platelet formation. Understanding the mechanisms of megakaryocyte differentiation and platelet formation can provide a solid theoretical basis for the treatment of platelet-related diseases. This review summarizes the current scientific research progress in the mechanisms of megakaryopoiesis and thrombopoiesis. Key words: Megakaryocytes; Cell differentiation; Thrombopoiesis; Transcription factors; Apoptosis; Megakaryopoiesis
{"title":"Recent advances in mechanisms of megakaryopoiesis and platelet formation","authors":"Rong Li","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.01.005","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.01.005","url":null,"abstract":"Platelets are specialized cells, which are functioned to prevent bleeding and minimize blood vessel injury, and are also the predominating factor in the processes of hemostasis and thrombosis, while implicate in other processes including inflammation, innate immunity, angiogenesis and tumor metastasis. Among current mechanisms of platelet formation, platelets are produced by megakaryocytes, which are themselves generated by a process of controlled differentiation and maturation of bone marrow hematopoietic stem cells (HSC) and progenitor cells. Megakaryocytes release platelets by extending long, branching proplatelets, into sinusoidal blood vessels. Bone marrow cavity and extracellular matrix composition together with cytokines as thrombopoietin (TPO) are key regulators of megakaryopoiesis by supporting cell differentiation and platelet formation. Understanding the mechanisms of megakaryocyte differentiation and platelet formation can provide a solid theoretical basis for the treatment of platelet-related diseases. This review summarizes the current scientific research progress in the mechanisms of megakaryopoiesis and thrombopoiesis. \u0000 \u0000 \u0000Key words: \u0000Megakaryocytes; Cell differentiation; Thrombopoiesis; Transcription factors; Apoptosis; Megakaryopoiesis","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"42 1","pages":"30-35"},"PeriodicalIF":0.0,"publicationDate":"2019-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48650032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-11-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2018.06.005
Hong Liu, Yong Zhang, Yan-yan Li
Objective To investigate the immunophenotypic characteristics of adult patients with initial treatment of acute myeloid leukemia (AML), as well as its relationship with curative effect. Methods A total of 167 adult patients with initial treatment of AML were randomly selected by computer generated random number method from January 2013 to December 2016 in Zibo Central Hospital of Shandong Province. Monoclonal antibody direct immunofluorescence labeling was used to label AML cell antigens of patients. The immunophenotypes of myeloid cell lines, lymphoid cell lines, and hematopoietic stem/progenitor cells of patients′ AML cells were analyzed by tricolor flow cytometry two-parameter scatter plot with CD45/side scatter (SSC). All AML patients were treated with conventional induction chemotherapy. After 1 course of chemotherapy, complete remission (CR) rates of patients were observed. The CR rates of AML patients of different immunophenotype were compared using χ2 test. The study protocol was approved by the Ethical Review Board of Investigation in Human Being of Zibo Central Hospital (Approval No. 2013-9). Informed consent was obtained from each participant. Results ① Among 167 adult patients with initial treatment of AML in this study, myeloid cell lines related antigens of positive expression rates from high to low were as follows: CD33 (90.4%, 151/167), CD13 (87.4%, 146/167), CD117 (79.0%, 132/167), myeloperoxidase (MPO) (71.3%, 119/167), CD64 (31.7%, 53/167), CD14 (21.6%, 36/167) and CD71 (4.2%, 7/167). The positive expression rates of CD14 and CD64 in 33 AML-M4 patients and 40 AML-M5 patients were high. The positive expression rates of CD14 and CD64 in AML-M4 patients were 24.2% (8/33) and 48.5% (16/33), respectively. And the positive expression rates of CD14 and CD64 in AML-M5 patients were 62.5% (25/40) and 77.5% (31/40), respectively. CD71 expressions were all positive in 5 AML-M6 patients. ② The hematopoietic stem/progenitor cells related antigens of positive expression rates from high to low in 167 adult patients with initial treatment of AML were as follows: CD38 (89.8%, 150/167), human leukocyte antigen (HLA)-DR (58.7%, 98/167), and CD34 (57.5%, 96/167). The positive expression rates of CD34 and HLA-DR were low in 34 AML-M3 patients, which were 5.9% (2/34) and 8.8% (3/34), respectively. ③ The lymphoid cell lines related antigens of positive expression rates from high to low in 167 adult patients with initial treatment of AML were as follows: CD7 (20.4%, 34/167), CD19 (13.8%, 23/167), CD4 (7.2%, 12/167), CD2 (4.2%, 7/167), CD10 (1.8%, 3/167), CD22 (1.2%, 2/167) and CD20 (0.6%, 1/167). ④ In all 167 adult patients with initial treatment of AML, 103 patients achieved CR with a CR rate of 61.7% after the first induction chemotherapy. In 133 patients with non-AML-M3 subtype, CR rates of AML patients with CD7 and CD34 positive expression were 51.5% (17/33) and 45.7% (43/94), which were lower than those of negative expression patient
{"title":"Immunophenotypic characteristics and prognosis of adult patients with initial treatment of acute myeloid leukemia","authors":"Hong Liu, Yong Zhang, Yan-yan Li","doi":"10.3760/CMA.J.ISSN.1673-419X.2018.06.005","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2018.06.005","url":null,"abstract":"Objective \u0000To investigate the immunophenotypic characteristics of adult patients with initial treatment of acute myeloid leukemia (AML), as well as its relationship with curative effect. \u0000 \u0000 \u0000Methods \u0000A total of 167 adult patients with initial treatment of AML were randomly selected by computer generated random number method from January 2013 to December 2016 in Zibo Central Hospital of Shandong Province. Monoclonal antibody direct immunofluorescence labeling was used to label AML cell antigens of patients. The immunophenotypes of myeloid cell lines, lymphoid cell lines, and hematopoietic stem/progenitor cells of patients′ AML cells were analyzed by tricolor flow cytometry two-parameter scatter plot with CD45/side scatter (SSC). All AML patients were treated with conventional induction chemotherapy. After 1 course of chemotherapy, complete remission (CR) rates of patients were observed. The CR rates of AML patients of different immunophenotype were compared using χ2 test. The study protocol was approved by the Ethical Review Board of Investigation in Human Being of Zibo Central Hospital (Approval No. 2013-9). Informed consent was obtained from each participant. \u0000 \u0000 \u0000Results \u0000① Among 167 adult patients with initial treatment of AML in this study, myeloid cell lines related antigens of positive expression rates from high to low were as follows: CD33 (90.4%, 151/167), CD13 (87.4%, 146/167), CD117 (79.0%, 132/167), myeloperoxidase (MPO) (71.3%, 119/167), CD64 (31.7%, 53/167), CD14 (21.6%, 36/167) and CD71 (4.2%, 7/167). The positive expression rates of CD14 and CD64 in 33 AML-M4 patients and 40 AML-M5 patients were high. The positive expression rates of CD14 and CD64 in AML-M4 patients were 24.2% (8/33) and 48.5% (16/33), respectively. And the positive expression rates of CD14 and CD64 in AML-M5 patients were 62.5% (25/40) and 77.5% (31/40), respectively. CD71 expressions were all positive in 5 AML-M6 patients. ② The hematopoietic stem/progenitor cells related antigens of positive expression rates from high to low in 167 adult patients with initial treatment of AML were as follows: CD38 (89.8%, 150/167), human leukocyte antigen (HLA)-DR (58.7%, 98/167), and CD34 (57.5%, 96/167). The positive expression rates of CD34 and HLA-DR were low in 34 AML-M3 patients, which were 5.9% (2/34) and 8.8% (3/34), respectively. ③ The lymphoid cell lines related antigens of positive expression rates from high to low in 167 adult patients with initial treatment of AML were as follows: CD7 (20.4%, 34/167), CD19 (13.8%, 23/167), CD4 (7.2%, 12/167), CD2 (4.2%, 7/167), CD10 (1.8%, 3/167), CD22 (1.2%, 2/167) and CD20 (0.6%, 1/167). ④ In all 167 adult patients with initial treatment of AML, 103 patients achieved CR with a CR rate of 61.7% after the first induction chemotherapy. In 133 patients with non-AML-M3 subtype, CR rates of AML patients with CD7 and CD34 positive expression were 51.5% (17/33) and 45.7% (43/94), which were lower than those of negative expression patient","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"41 1","pages":"485-491"},"PeriodicalIF":0.0,"publicationDate":"2018-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42589119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-11-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2018.06.011
A. Sun, Guangsen Zhang
Circular RNA (circRNA) is a group of widely existed endogenous non-coding RNA. Its main structural feature is closed covalently cyclic loops and lack of the 5′-end, the 3′-end, and poly (A) tail, which resistant to degradation by RNA exonucleases and avoid debranching by adenylate debranching enzymes. Therefore, circRNA is stable in structure and function. Recent researches have revealed that circRNA mainly participates in transcriptional and posttranscriptional regulation, especially acts as microRNA (miRNA) sponge to regulate target gene expression as competitive endogenous RNA (ceRNA). circRNA is directly or indirectly involved in development of hematopoiesis in marrow and hematological malignancies, and is expected as a new diagnostic biomarker or molecular therapeutic target for hematological malignancies. In order to investigate relationships between circRNA and malignant transformation, therapeutic efficacy and prognosis of hematologic malignancies, this review summarizes the classification, characteristics, biological functions of circRNA and its role in hematopoiesis and hematologic malignancies. Key words: RNA, untranslated; microRNAs; Hematopoiesis; Hematologic neoplasms; Biological markers; circRNA
{"title":"Research progress of circular RNA and its roles in hematological malignancies","authors":"A. Sun, Guangsen Zhang","doi":"10.3760/CMA.J.ISSN.1673-419X.2018.06.011","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2018.06.011","url":null,"abstract":"Circular RNA (circRNA) is a group of widely existed endogenous non-coding RNA. Its main structural feature is closed covalently cyclic loops and lack of the 5′-end, the 3′-end, and poly (A) tail, which resistant to degradation by RNA exonucleases and avoid debranching by adenylate debranching enzymes. Therefore, circRNA is stable in structure and function. Recent researches have revealed that circRNA mainly participates in transcriptional and posttranscriptional regulation, especially acts as microRNA (miRNA) sponge to regulate target gene expression as competitive endogenous RNA (ceRNA). circRNA is directly or indirectly involved in development of hematopoiesis in marrow and hematological malignancies, and is expected as a new diagnostic biomarker or molecular therapeutic target for hematological malignancies. In order to investigate relationships between circRNA and malignant transformation, therapeutic efficacy and prognosis of hematologic malignancies, this review summarizes the classification, characteristics, biological functions of circRNA and its role in hematopoiesis and hematologic malignancies. \u0000 \u0000 \u0000Key words: \u0000RNA, untranslated; microRNAs; Hematopoiesis; Hematologic neoplasms; Biological markers; circRNA","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"41 1","pages":"520-524"},"PeriodicalIF":0.0,"publicationDate":"2018-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41710943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-11-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2018.06.010
Lixia Fu, Yingshao Wang
Polycythemia vera (PV) is representative in Ph- myeloproliferative neoplasm (MPN), which is characterized by increasing of two or three line blood cells, especially erythrocytosis. First, during the occurrence and progression of PV, JAK2, TET2, IDH1/2 and ASXL1 gene mutation and associated epigenetic changes play an important role. Besides, abnormal cytokines produced by chronic inflammation can promote the malignant transformation of hematopoietic stem cells (HSC), which may also be one of the important mechanisms of PV occurrence. Moreover, the changes in hematopoietic microenvironment were also associated with the progression of post-PV myelofibrosis(MF). This article reviews the pathogenesis of PV from several aspects that involve genes mutation, chronic inflammation and the changing of hematopoietic microenvironment. Key words: Polycythemia vera; Hematopoietic stem cells; Mutation; Cytokines; Tumor microenvironment
{"title":"Research progress of pathogenesis in polycythemia vera","authors":"Lixia Fu, Yingshao Wang","doi":"10.3760/CMA.J.ISSN.1673-419X.2018.06.010","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2018.06.010","url":null,"abstract":"Polycythemia vera (PV) is representative in Ph- myeloproliferative neoplasm (MPN), which is characterized by increasing of two or three line blood cells, especially erythrocytosis. First, during the occurrence and progression of PV, JAK2, TET2, IDH1/2 and ASXL1 gene mutation and associated epigenetic changes play an important role. Besides, abnormal cytokines produced by chronic inflammation can promote the malignant transformation of hematopoietic stem cells (HSC), which may also be one of the important mechanisms of PV occurrence. Moreover, the changes in hematopoietic microenvironment were also associated with the progression of post-PV myelofibrosis(MF). This article reviews the pathogenesis of PV from several aspects that involve genes mutation, chronic inflammation and the changing of hematopoietic microenvironment. \u0000 \u0000 \u0000Key words: \u0000Polycythemia vera; Hematopoietic stem cells; Mutation; Cytokines; Tumor microenvironment","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"41 1","pages":"515-519"},"PeriodicalIF":0.0,"publicationDate":"2018-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46671481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-11-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2018.06.007
Zhan-Rou Quan, Z. Deng, Dan Zhou, Y-P Zhong, Hao Chen, Hong Wenxu
Objective To explore the human leukocyte antigen (HLA)-A, -B, -C, -DRB1 and -DQB1 high-resolution alleles polymorphism in hematopoietic stem cells donors of Chinese Han population from Southern China. Methods A total of 4 262 cases hematopoietic stem cell donors of chinese Han population in Shenzhen China Marrow Donor Program (CMDP) from January 2016 to December 2017 were selected as subjects. HLA-A, -B, -C, -DRB1 and -DQB1 loci for high resolution typing of these 4 262 cases hematopoietic stem cell donors were detected by PCR-sequence-specific oligonucleotide probes (SSO) and next-generation sequencing (NGS) analysis. The frequencies of common, well-documented and rare alleles were studied by direct counting method. The χ2 test was used to determine whether the distribution of HLA-A, -B, -C, -DRB1 and -DQB1 alleles of these 4 262 cases hematopoietic stem cell donors accorded with the Hardy-Weinberg equilibrium. Results ① Compared observed values of HLA-A, -B, -C, -DRB1 and -DQB1 alleles in these 4 262 cases hematopoietic stem cell donors of Chinese Han population from Southern China with the expected values, there were not statistically significance (χ2=295.068, 572.482, 355.205, 362.584, 312.150; P>0.05), which indicated that the distribution of HLA-A, -B, -C, -DRB1 and -DQB1 alleles of all hematopoietic stem cell donors in this study conformed with Hardy-Weinberg equilibrium. ② The alleles of HLA-A, -B, -C, -DRB1 and -DQB1 loci in 4 262 cases hematopoietic stem cells donors of Chinese Han population from Southern China were 49, 97, 37, 48 and 22, respectively. Among them, the common alleles with frequencies higher than 0.05 included HLA-A*11∶01, 24∶02, 02∶07, 02∶01, 33∶03 and 02∶03; HLA-B*40∶01, 46∶01, 58∶01, 13∶01 and 51∶01; HLA-C*01∶02, 07∶02, 03∶04, 08∶01, 03∶02, 06∶02 and 03∶03; HLA-DRB1*09∶01, 15∶01, 12∶02, 07∶01, 08∶03, 03∶01, 11∶01 and 04∶05; and HLA-DQB1*03∶01, 03∶03, 06∶01, 05∶02, 03∶02, 02∶01, 05∶03, 06∶02 and 02∶02. For each of the locus, the cumulative allele frequencies of common alleles were 0.767 1, 0.471 6, 0.782 5, 0.656 4 and 0.877 6, respectively. ③ The well-documented and rare alleles of HLA-A, -B, -C, -DRB1 and -DQB1 loci were detected as 22, 42, 14, 11 and 7. Among them, the rare alleles of HLA-A*29∶03; HLA-B*18∶04, 15∶296 and 54∶03; HLA-C*12∶12; HLA-DRB1*04∶101 and HLA-DQB1*02∶10 were not included in the Common Alleles and Well-Documented Alleles (CWD) v2.3 of CMDP. Conclusions Relatively complete high-resolution allelic distribution data of HLA-A, -B, -C -DRB1 and -DQB1 loci in hematopoietic stem cells donors of Chinese Han population from Southern China were obtained in this study. And HLA well-documented and rare alleles were recorded. The results of this study contribute to the accumulation on population distribution and polymorphism data of HLA gene in hematopoietic stem cell donors, and provide reference for improving CWD of CMDP. Key words: HLA antigens; Alleles; Gene frequency; Polymerase
目的探讨中国南方汉族造血干细胞捐献者的人类白细胞抗原（HLA）-A、-B、-C、-DRB1和-DQB1高分辨率等位基因多态性。方法选取2016年1月至2017年12月深圳市中华骨髓捐献者计划（CMDP）的4622例中国汉族造血干细胞捐献者作为受试者。采用聚合酶链式反应序列特异性寡核苷酸探针（SSO）和下一代测序（NGS）分析方法，检测了4 262例造血干细胞捐献者的HLA-A、-B、-C、-DRB1和-DQB1位点的高分辨率分型。用直接计数法研究了常见等位基因、文献记载的等位基因和罕见等位基因的频率。应用χ2检验确定4 262例造血干细胞捐献者的HLA-A、-B、-C、-DRB1和-DQB1等位基因的分布是否符合Hardy-Weinberg平衡。结果①中国南方汉族4 262例造血干细胞捐献者HLA-A、-B、-C、-DRB1和-DQB1等位基因的观察值与预期值比较，无统计学意义（χ2=295.068、572.482、355.205、362.584、312.150；P>0.05），本研究所有造血干细胞捐献者的-DRB1和-DQB1等位基因均符合Hardy-Weinberg平衡中国南方汉族4 262例造血干细胞捐献者的HLA-A、-B、-C、-DRB1和-DQB1等位基因分别为49、97、37、48和22。其中，频率高于0.05的常见等位基因包括HLA-A*11∶01、24∶02、02∶07、02∶01、33∶03和02∶03；HLA-B*40∶01、46∶01、58∶01、13∶01和51∶01；HLA-C*01∶02、07∶02、03∶04、08∶01、03∶02、06∶02和03∶03；HLA-DRB1*09∶01、15∶01、12∶02、07∶01、08∶03、03∶01、11∶01和04∶05；HLA-DQB1*03∶01、03∶03、06∶01、05∶02、03∶02、02∶01、06∶03和02∶02。每个位点的常见等位基因的累积等位基因频率分别为0.7671、0.4716、0.7825、0.6564和0.8776HLA-A、-B、-C、-DRB1和-DQB1等位基因座的罕见等位基因分别为22、42、14、11和7。其中HLA-A*29∶03为罕见等位基因；HLA-B*18∶04、15∶296和54∶03；HLA-C*12∶12；HLA-DRB1*04∶101和HLA-DQB1*02∶10不包含在CMDP的Common Alleles and Well Documented Alleles（CWD）v2.3中。结论本研究获得了中国南方汉族造血干细胞捐献者HLA-A、-B、-C-DRB1和-DQB1等位基因相对完整的高分辨率等位基因分布数据。HLA等位基因记录丰富且罕见。本研究结果有助于积累造血干细胞捐献者HLA基因的群体分布和多态性数据，为改善CMDP的CWD提供参考。关键词：HLA抗原；Alleles；基因频率；聚合酶链式反应；高分辨率基因分型；常见等位基因；有充分记录的等位基因；稀有等位基因；聚合酶链式反应序列特异性寡核苷酸；下一代测序
{"title":"Analysis on polymorphism of high-resolution HLA-A, -B, -C, -DRB1 and -DQB1 in hematopoietic stem cells donors of Chinese Han population from Southern China","authors":"Zhan-Rou Quan, Z. Deng, Dan Zhou, Y-P Zhong, Hao Chen, Hong Wenxu","doi":"10.3760/CMA.J.ISSN.1673-419X.2018.06.007","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2018.06.007","url":null,"abstract":"Objective \u0000To explore the human leukocyte antigen (HLA)-A, -B, -C, -DRB1 and -DQB1 high-resolution alleles polymorphism in hematopoietic stem cells donors of Chinese Han population from Southern China. \u0000 \u0000 \u0000Methods \u0000A total of 4 262 cases hematopoietic stem cell donors of chinese Han population in Shenzhen China Marrow Donor Program (CMDP) from January 2016 to December 2017 were selected as subjects. HLA-A, -B, -C, -DRB1 and -DQB1 loci for high resolution typing of these 4 262 cases hematopoietic stem cell donors were detected by PCR-sequence-specific oligonucleotide probes (SSO) and next-generation sequencing (NGS) analysis. The frequencies of common, well-documented and rare alleles were studied by direct counting method. The χ2 test was used to determine whether the distribution of HLA-A, -B, -C, -DRB1 and -DQB1 alleles of these 4 262 cases hematopoietic stem cell donors accorded with the Hardy-Weinberg equilibrium. \u0000 \u0000 \u0000Results \u0000① Compared observed values of HLA-A, -B, -C, -DRB1 and -DQB1 alleles in these 4 262 cases hematopoietic stem cell donors of Chinese Han population from Southern China with the expected values, there were not statistically significance (χ2=295.068, 572.482, 355.205, 362.584, 312.150; P>0.05), which indicated that the distribution of HLA-A, -B, -C, -DRB1 and -DQB1 alleles of all hematopoietic stem cell donors in this study conformed with Hardy-Weinberg equilibrium. ② The alleles of HLA-A, -B, -C, -DRB1 and -DQB1 loci in 4 262 cases hematopoietic stem cells donors of Chinese Han population from Southern China were 49, 97, 37, 48 and 22, respectively. Among them, the common alleles with frequencies higher than 0.05 included HLA-A*11∶01, 24∶02, 02∶07, 02∶01, 33∶03 and 02∶03; HLA-B*40∶01, 46∶01, 58∶01, 13∶01 and 51∶01; HLA-C*01∶02, 07∶02, 03∶04, 08∶01, 03∶02, 06∶02 and 03∶03; HLA-DRB1*09∶01, 15∶01, 12∶02, 07∶01, 08∶03, 03∶01, 11∶01 and 04∶05; and HLA-DQB1*03∶01, 03∶03, 06∶01, 05∶02, 03∶02, 02∶01, 05∶03, 06∶02 and 02∶02. For each of the locus, the cumulative allele frequencies of common alleles were 0.767 1, 0.471 6, 0.782 5, 0.656 4 and 0.877 6, respectively. ③ The well-documented and rare alleles of HLA-A, -B, -C, -DRB1 and -DQB1 loci were detected as 22, 42, 14, 11 and 7. Among them, the rare alleles of HLA-A*29∶03; HLA-B*18∶04, 15∶296 and 54∶03; HLA-C*12∶12; HLA-DRB1*04∶101 and HLA-DQB1*02∶10 were not included in the Common Alleles and Well-Documented Alleles (CWD) v2.3 of CMDP. \u0000 \u0000 \u0000Conclusions \u0000Relatively complete high-resolution allelic distribution data of HLA-A, -B, -C -DRB1 and -DQB1 loci in hematopoietic stem cells donors of Chinese Han population from Southern China were obtained in this study. And HLA well-documented and rare alleles were recorded. The results of this study contribute to the accumulation on population distribution and polymorphism data of HLA gene in hematopoietic stem cell donors, and provide reference for improving CWD of CMDP. \u0000 \u0000 \u0000Key words: \u0000HLA antigens; Alleles; Gene frequency; Polymerase","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"41 1","pages":"497-505"},"PeriodicalIF":0.0,"publicationDate":"2018-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45646038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-11-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2018.06.013
D. Zheng
Histone acetyltransferase (HAT) and histone deacetylase (HDAC) are involved in cell cycle regulation, cell proliferation and survival, cell differentiation, cell metabolism, protein trafficking, DNA repair and angiogenesis. Imbalance of HAT and HDAC is associated with the occurrence of some tumors. Therefore, various targeted drugs targeting the HDAC family may be effective for tumor treatment. This article will review the progress of chidamide, compared with the other histone deacetylase inhibitor (HDACi), in the treatment of hematological diseases such as lymphoma, leukemia, myelodysplastic syndrome (MDS), and multiple myeloma (MM). And these new drugs can serve the clinical practice in a better way. Key words: Histone deacetylase inhibitors; Hematologic neoplasms; Molecular targeted therapy; Chidamide; Treatment
{"title":"Advances in research of histone deacetylase inhibitors in treatment of hematological diseases","authors":"D. Zheng","doi":"10.3760/CMA.J.ISSN.1673-419X.2018.06.013","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2018.06.013","url":null,"abstract":"Histone acetyltransferase (HAT) and histone deacetylase (HDAC) are involved in cell cycle regulation, cell proliferation and survival, cell differentiation, cell metabolism, protein trafficking, DNA repair and angiogenesis. Imbalance of HAT and HDAC is associated with the occurrence of some tumors. Therefore, various targeted drugs targeting the HDAC family may be effective for tumor treatment. This article will review the progress of chidamide, compared with the other histone deacetylase inhibitor (HDACi), in the treatment of hematological diseases such as lymphoma, leukemia, myelodysplastic syndrome (MDS), and multiple myeloma (MM). And these new drugs can serve the clinical practice in a better way. \u0000 \u0000 \u0000Key words: \u0000Histone deacetylase inhibitors; Hematologic neoplasms; Molecular targeted therapy; Chidamide; Treatment","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"41 1","pages":"530-534"},"PeriodicalIF":0.0,"publicationDate":"2018-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48698788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-11-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2018.06.009
Zhiyang Liu, Xu-liang Shen
Early/prefibrotic primary myelofibrosis (pre-PMF) is an early stage of primary myelofibrosis (PMF). It is a myeloproliferative neoplasms (MPN) with inert clinical manifestations and good prognosis. Diagnosis of pre-PMF mainly depends on bone marrow morphology and secondary clinical criteria. Patients with Pre-PMF have a better prognosis than those of PMF patients. This article reviews the research progress of bone marrow morphology, clinical and laboratory characteristics, gene mutation and load, treatment and prognosis of pre-PMF in order to improve understanding and diagnosis of the disease. Key words: Primary myelofibrosis; Megakaryocytes; Gene expression regulation; Drug therapy; Hematopoietic stem cell transplantation; Prognosis
{"title":"Research progress of early/prefibrotic primary myelofibrosis","authors":"Zhiyang Liu, Xu-liang Shen","doi":"10.3760/CMA.J.ISSN.1673-419X.2018.06.009","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2018.06.009","url":null,"abstract":"Early/prefibrotic primary myelofibrosis (pre-PMF) is an early stage of primary myelofibrosis (PMF). It is a myeloproliferative neoplasms (MPN) with inert clinical manifestations and good prognosis. Diagnosis of pre-PMF mainly depends on bone marrow morphology and secondary clinical criteria. Patients with Pre-PMF have a better prognosis than those of PMF patients. This article reviews the research progress of bone marrow morphology, clinical and laboratory characteristics, gene mutation and load, treatment and prognosis of pre-PMF in order to improve understanding and diagnosis of the disease. \u0000 \u0000 \u0000Key words: \u0000Primary myelofibrosis; Megakaryocytes; Gene expression regulation; Drug therapy; Hematopoietic stem cell transplantation; Prognosis","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"41 1","pages":"511-514"},"PeriodicalIF":0.0,"publicationDate":"2018-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45002037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-11-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2018.06.015
Yimeng Niu, Yan Li
Therapy-related myeloid leukemia (TRML) is a secondary myeloid leukemia after the primary disease. It is a subtype of myeloid leukemia with high morbidity and case fatality rate. The prognosis of patients with TRML is poor, the median survival time is short, and the traditional treatment is not effective. With the deepening of the research on this disease, various new therapies, such as targeted therapy, immunotherapy, allogeneic hematopoietic stem cell transplantation (allo-HSCT) and other therapies have emerged constantly, which provide a new reference and research direction for the treatment of TRML. Progress on the pathogenesis, individualized diagnosis, treatment and prognosis evaluation of TRML were reviewed for clinical reference. Key words: Leukemia, myeloid; Neoplasms, second primary; Precision medicine; Molecular targeted therapy; Hematopoietic stem cell transplantation; Immunotherapy
{"title":"Advances in therapy-related myeloid leukemia","authors":"Yimeng Niu, Yan Li","doi":"10.3760/CMA.J.ISSN.1673-419X.2018.06.015","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2018.06.015","url":null,"abstract":"Therapy-related myeloid leukemia (TRML) is a secondary myeloid leukemia after the primary disease. It is a subtype of myeloid leukemia with high morbidity and case fatality rate. The prognosis of patients with TRML is poor, the median survival time is short, and the traditional treatment is not effective. With the deepening of the research on this disease, various new therapies, such as targeted therapy, immunotherapy, allogeneic hematopoietic stem cell transplantation (allo-HSCT) and other therapies have emerged constantly, which provide a new reference and research direction for the treatment of TRML. Progress on the pathogenesis, individualized diagnosis, treatment and prognosis evaluation of TRML were reviewed for clinical reference. Key words: Leukemia, myeloid; Neoplasms, second primary; Precision medicine; Molecular targeted therapy; Hematopoietic stem cell transplantation; Immunotherapy","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"41 1","pages":"539-542"},"PeriodicalIF":0.0,"publicationDate":"2018-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46494128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-11-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2018.06.014
C. Ling, Qi-Chuan Jin, W. Gong, Qi-guo Zhang
Pyroptosis is the programmed cell death mediated by inflammatory cysteine-aspartic protease (Caspase). Intercallular or extracellular pathogens can promote the formation of inflammatory by activating Caspase-1, Caspase-4/5/11, pro-interleukin (IL)-1β and pro-IL-18. The activated inflammatory cytokines lead to cell lysis and inflammatory factors release, and finally induced cell death.The alterations of Toll like receptor(TLR) signaling pathway and bone microenvironment, and presence of inflammasome could cause the formation of an inflammatory environment, leading to myelodyplastic syndrome (MDS). The article reviews the mechanism of pyroptosis and the relationship between pyroptosis and MDS. Key words: Pyroptosis; Myelodyplastic syndrome; Caspases; Interleukin-1beta; Interleukin-18
焦亡是由炎性半胱氨酸-天冬氨酸蛋白酶(Caspase)介导的程序性细胞死亡。细胞间或细胞外病原体可通过激活Caspase-1、Caspase-4/5/11、IL -1β和IL-18促进炎症的形成。被激活的炎性因子导致细胞裂解和炎性因子释放，最终诱导细胞死亡。Toll样受体(Toll like receptor, TLR)信号通路和骨微环境的改变以及炎性小体的存在可引起炎症环境的形成，从而导致骨髓增生综合征(myelelodyplastic syndrome, MDS)。本文就热亡的发生机制及热亡与MDS的关系作一综述。关键词:焦亡;Myelodyplastic综合症;还存在;Interleukin-1beta;Interleukin-18
{"title":"Research progress on role of pyroptosis in pathogenesis of myelodyplastic syndrome","authors":"C. Ling, Qi-Chuan Jin, W. Gong, Qi-guo Zhang","doi":"10.3760/CMA.J.ISSN.1673-419X.2018.06.014","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2018.06.014","url":null,"abstract":"Pyroptosis is the programmed cell death mediated by inflammatory cysteine-aspartic protease (Caspase). Intercallular or extracellular pathogens can promote the formation of inflammatory by activating Caspase-1, Caspase-4/5/11, pro-interleukin (IL)-1β and pro-IL-18. The activated inflammatory cytokines lead to cell lysis and inflammatory factors release, and finally induced cell death.The alterations of Toll like receptor(TLR) signaling pathway and bone microenvironment, and presence of inflammasome could cause the formation of an inflammatory environment, leading to myelodyplastic syndrome (MDS). The article reviews the mechanism of pyroptosis and the relationship between pyroptosis and MDS. \u0000 \u0000 \u0000Key words: \u0000Pyroptosis; Myelodyplastic syndrome; Caspases; Interleukin-1beta; Interleukin-18","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"41 1","pages":"535-538"},"PeriodicalIF":0.0,"publicationDate":"2018-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69910348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：